CORE B - SUMMARY/ABSTRACT
Core B will provide antibody-coated nanoparticles (NPs) and FRCs for in vivo administration to reprogram the
LN microenvironment towards a regulatory milieu that promotes transplant tolerance. These strategies
represent cutting-edge approaches which have been set forth only by the teams here, and hence they
represent a radical departure from the traditional approaches to induce tolerance. These techniques provided
by Core B lay the groundwork for developing first class of therapeutics aimed towards reprogramming the
microenvironment of the LN. In addition to the applications of these data to transplantation, they can also have
a major impact in other immune conditions in which the LN plays a central role in the pathogenesis (e.g.,
autoimmune diseases and tumor immunity). This Core will fully characterize and synthesize large quantities of
MECA-79-conjugated carriers of anti-laminin α5 (LAMA5) and anti-CD40L mAbs (Project 2 - Bromberg), as
well as senolytic agents (SAs) (Project 1- Abdi). Core B will also synthesize dye-incorporating NPs (including
infrared dye) to verify trafficking to LNs as well as to control the quality of the batches. This will be the first
platform that targets LNs for drug delivery to reprogram their microenvironment towards immune tolerance. In
addition, Core B will expand FRCs isolated from the LNs of healthy mice and will be fully characterized for
FRC-specific markers. These cells will be provided to Project 1 for experiments that assess their impact on
downregulating LN fibrosis and its deleterious effects on transplant tolerance.
The specific aims of Core B are as follows:
Aim 1. To characterize and provide antibody-conjugated NPs for targeted delivery of immune
therapeutics to the LN to promote transplant tolerance.
Aim 2. To characterize and provide healthy FRCs for in vivo administration to promote transplant
tolerance by reprogramming the LN microenvironment.
Public Health Relevance Statement
CORE B- Narrative
Core B will be responsible for synthesizing and characterizing the NPs and FRCs. Core B will be utilized by
both projects.
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
030811269
UEI
QN6MS4VN7BD1
Project Start Date
27-July-2020
Project End Date
30-June-2025
Budget Start Date
01-July-2024
Budget End Date
30-June-2025
Project Funding Information for 2024
Total Funding
$176,467
Direct Costs
$104,234
Indirect Costs
$72,233
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$176,467
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P01AI153003-05 6326
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P01AI153003-05 6326
Patents
No Patents information available for 5P01AI153003-05 6326
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P01AI153003-05 6326
Clinical Studies
No Clinical Studies information available for 5P01AI153003-05 6326
News and More
Related News Releases
No news release information available for 5P01AI153003-05 6326
History
No Historical information available for 5P01AI153003-05 6326
Similar Projects
No Similar Projects information available for 5P01AI153003-05 6326